<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914158</url>
  </required_header>
  <id_info>
    <org_study_id>20160818GD</org_study_id>
    <nct_id>NCT02914158</nct_id>
  </id_info>
  <brief_title>Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women</brief_title>
  <acronym>ASPAIT</acronym>
  <official_title>Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen for Hormone Receptor-Positive Breast Cancer in Women Younger Than 35: A Multicenter Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the curative effects in patients under the age of
      35 with hormone receptor positive breast cancer and high recurrent risk factors including
      large tumor or metastatic lymph nodes randomized to ovarian function suppression (OFS) plus
      aromatase inhibitors or OFS plus tamoxifen as adjuvant endocrine therapy, and explore the
      differences of curative effects between different subtypes to provide direct evidence for
      treatments of young breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DFS is defined as the time between randomization and the date of the first occurrence of events as follow: local, regional recurrence or distant metastasis of invasive breast cancer, contralateral invasive breast cancer, or death due to any diseases. Patients who have not had disease progression or death at the end of follow-up (5 years) will be censored at the date last known to be alive and distant metastasis free. Subgroup analysis DFS of Luminal A and Luminal B breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>The time from randomization to death due to any cause. Patients still alive at the end of follow-up (5 years) will be censored at the last known alive date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive Breast Cancer Recurrence-Free Interval（BCFI)</measure>
    <time_frame>5 years</time_frame>
    <description>The time between randomization and the first occurrence of local, regional recurrence or distant metastasis of invasive breast cancer, or contralateral invasive breast cancer. Patients who have not had invasive breast cancer recurrence at the end of follow-up (5 years) will be censored at the date last known to be distant metastasis free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects Rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Goserelin and aromatase inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.
AI: no restriction of specific drugs, oral by standard dose of post-menopause breast cancer, for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Goserelin and tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.
Tamoxifen: 20mg oral for every day, for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <arm_group_label>Goserelin and aromatase inhibitors</arm_group_label>
    <arm_group_label>Goserelin and tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <arm_group_label>Goserelin and tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitors</intervention_name>
    <arm_group_label>Goserelin and aromatase inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent;

          2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;

          3. Patients pathologically diagnosed with hormone receptor positive invasive breast
             cancer: immunohistochemistry ER positive (≥1%);

          4. Premenopausal patients with age ≤35 years (at least menstruate once for prior 3
             months, assess menstruation situation before chemotherapy if have);

          5. No distant metastasis;

          6. Clinical stage (TNM) meets at least one of the conditions as follow: T≥2cm or at least
             one region of regional lymph node metastasis (including micrometastases);

          7. Patients must have undergone a surgery and (neo)adjuvant chemotherapy, targeted
             therapy, radiotherapy (if necessary) according to Chinese Anti-Cancer Association
             guidelines and specifications version 2015 for diagnosis and treatment of breast
             cancer;

          8. Indexes of hematology and biochemistry conform to following standards: HGB≥10g/dl,
             WBC≥4,000/mm3, PLT≥100,000/mm3, GOT, GPT, ALP≤2xULN, TBIL, DBIL, CCr≤1.5xULN.

        Exclusion Criteria:

          1. Pregnant or lactating women or women of childbearing potential reject contraceptive
             measures;

          2. History of organ transplantation (including autologous bone marrow transplantation and
             peripheral stem cell transplantation);

          3. Concurrent malignancies or history of non-breast malignancies within the 5 years prior
             to study entry, except for curatively treated basal cell and squamous cell carcinomas
             of the skin, carcinoma in situ of the cervix; peripheral nervous system disorders
             caused by diseases or history of obvious mental and central nervous system disorders;

          4. Prior use of neo-adjuvant chemotherapy after a definite diagnosis;

          5. Nervous system disorders caused by diseases or obvious mental disorder, which would
             affect patients right to consent and compliance, or make patients in critical
             condition;

          6. Serious hepatopathy (e.g., cirrhosis, etc.), nephropathy, respiratory illness,
             digestive illness or poorly controlled diabetes;

          7. Cardiac illness with obvious abnormal EKG or clinical symptoms, namely congestive
             heart failure, coronary atherosclerotic heart disease with obvious symptoms,
             arrhythmia difficult to control by drugs, or history of myocardial infarction within
             the 12 months prior to study entry or class III/IV of cardiac function;

          8. Concurrent treatment in another investigational trial;

          9. Sensitivity or contraindication to any of the study medications.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Ying, doctor</last_name>
    <phone>020-28823235</phone>
    <email>frostlin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen R Ping, bachelor</last_name>
    <phone>13533242895</phone>
    <email>ruping089@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ailing Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GuangDong Hospital Of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianjun Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Women and Children's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang A Qin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First Municipal People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Women and Childrens Medical Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao H Rui</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Z Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lehong Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guilin TCMhospital of China</name>
      <address>
        <city>Guilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Zhuo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Cai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maoming People's Hospital</name>
      <address>
        <city>Maoming</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weixiong Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingcai Zhong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated hospital of Guangdong Medicine College</name>
      <address>
        <city>Zhanjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li J Wen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated hospital of Guangdong Medicine College</name>
      <address>
        <city>Zhanjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Y Qi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lian Jiang People' s Hospital</name>
      <address>
        <city>Zhanjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Heng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongshan People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feihai Ling</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital Sun Yat-Sen University</name>
      <address>
        <city>Zhuhai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014 Jun;15(7):e279-89. doi: 10.1016/S1470-2045(13)70567-9. Review.</citation>
    <PMID>24872111</PMID>
  </reference>
  <reference>
    <citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015 Oct 3;386(10001):1341-1352. doi: 10.1016/S0140-6736(15)61074-1. Epub 2015 Jul 23.</citation>
    <PMID>26211827</PMID>
  </reference>
  <reference>
    <citation>LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007 May 19;369(9574):1711-23.</citation>
    <PMID>17512856</PMID>
  </reference>
  <reference>
    <citation>Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.</citation>
    <PMID>24881463</PMID>
  </reference>
  <reference>
    <citation>Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.</citation>
    <PMID>25495490</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Ying Lin</investigator_full_name>
    <investigator_title>Vice Director of Department of Breast Surgery</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>ovarian function suppression (OFS)</keyword>
  <keyword>aromatase inhibitors（AIs）</keyword>
  <keyword>tamoxifen（TAM）</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

